Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 10/20 | 0.43 |
| ▸ | RXRB | P28702 | 9/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.43 |
| ▸ | RXRG | P48443 | 5/20 | 0.41 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.38 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3452356 | 0.94 | RXRA (0.41) | RXRARXRBNR4A2RXRGNR4A1 | |
| SCHEMBL930643 | 0.87 | RXRA (0.50) | RXRARXRBNR4A2RXRGNR4A1 | |
| SCHEMBL3453032 | 0.82 | RXRA (0.40) | RXRARXRBNR4A2RXRGNR4A1 | |
| SCHEMBL3452018 | 0.82 | RXRA (0.40) | RXRARXRBNR4A2RXRGNR4A1 | |
| SCHEMBL3452350 | 0.81 | ALOX5AP (0.36) | RXRARXRBNR4A2RXRGNR4A1 | |
| SCHEMBL2192978 | 0.80 | RXRA (0.34) | RXRARXRBNR4A2RXRGNPC1 | |
| SCHEMBL3453718 | 0.78 | RXRA (0.41) | RXRARXRBNR4A2RXRGNR4A1 | |
| SCHEMBL929990 | 0.78 | RXRA (0.49) | RXRARXRBRXRGNPC1POLB | |
| SCHEMBL930478 | 0.78 | RXRA (0.49) | RXRARXRBRXRGNPC1POLB | |
| SCHEMBL2192012 | 0.77 | THRA (0.38) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875743-B2 | such as bis(3-formyl-4-(4-methoxycarbonylphenyl)methoxyphenyl)methane, by reacting bis(hydroxymethyl-hydroxyphenyl)alkane with hexamethylene tetramine in presence of acid and hydrolyzing, then reacting with halogenated alkoxycarbonyl hydrocarbon in presence of base | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2011-01-25 | — | — | US | claimed |
| US-20100016633-A1 | such as bis(3-formyl-4-(4-methoxycarbonylphenyl)methoxyphenyl)methane, by reacting bis(hydroxymethyl-hydroxyphenyl)alkane with hexamethylene tetramine in presence of acid and hydrolyzing, then reacting with halogenated alkoxycarbonyl hydrocarbon in presence of base | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2010-01-21 | — | — | US | claimed |
| US-7875743-B2 | such as bis(3-formyl-4-(4-methoxycarbonylphenyl)methoxyphenyl)methane, by reacting bis(hydroxymethyl-hydroxyphenyl)alkane with hexamethylene tetramine in presence of acid and hydrolyzing, then reacting with halogenated alkoxycarbonyl hydrocarbon in presence of base | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2011-01-25 | — | — | US | disclosed |
| US-20100016633-A1 | such as bis(3-formyl-4-(4-methoxycarbonylphenyl)methoxyphenyl)methane, by reacting bis(hydroxymethyl-hydroxyphenyl)alkane with hexamethylene tetramine in presence of acid and hydrolyzing, then reacting with halogenated alkoxycarbonyl hydrocarbon in presence of base | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016633-A1 | such as bis(3-formyl-4-(4-methoxycarbonylphenyl)methoxyphenyl)methane, by reacting bis(hydroxymethyl-hydroxyphenyl)alkane with hexamethylene tetramine in presence of acid and hydrolyzing, then reacting with halogenated alkoxycarbonyl hydrocarbon in presence of base | PAH, PGM2, HNMT | RXRA 2980/4885RXRB 3023/4885NR4A2 2081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.